Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
COLUMN
How Can Innovative Field Force Roles and Ways of Working Create More Impactful Engagement?
Introduction In my second column I discussed the importance of channel orchestration to improve productivity and engagement experience across a pharmaceutical company’s real and digital channels. In this column I analyze how top performing companies are evolving their field forces…
To read the full story
Related Article
COLUMN
- A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
- How to Be a Country Manager
November 29, 2024
- Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
- Why LinkedIn Isn’t Effective in Japan
August 27, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…